Overview

Centrophenoxine, marketed under the name meclofenoxate, is a synthetic ester of dimethylaminoethanol (DMAE) and para-chlorophenoxyacetic acid (pCPA). Developed in 1959 at the French National Scientific Research Center, it was originally investigated as a treatment for age-related cognitive decline. The compound is designed to be more bioavailable than DMAE alone, readily crossing the blood-brain barrier to exert its effects on central nervous system function.

The primary mechanism of interest involves centrophenoxine's ability to reduce lipofuscin, an age-related pigment that accumulates in neurons and other cells over time. By facilitating the removal of this cellular waste product, centrophenoxine may help maintain neuronal health during aging. Additionally, as a precursor to DMAE, it may support the synthesis of acetylcholine, a neurotransmitter critical for memory and learning processes.

Centrophenoxine has been the subject of numerous preclinical studies and some clinical investigations, particularly in elderly populations with cognitive impairment. While results have shown modest improvements in memory and alertness in certain studies, the overall body of clinical evidence remains limited by small sample sizes and methodological variability. It is available as a dietary supplement in many countries and is generally considered to have a favorable safety profile at standard doses.

Mechanism of Action

DMAE Ester — Cholinergic Precursor

Centrophenoxine (meclofenoxate) is an ester of dimethylaminoethanol (DMAE) and para-chlorophenoxyacetic acid (pCPA), a synthetic plant growth hormone analog. Following oral absorption, centrophenoxine is rapidly cleaved by plasma esterases into its two components. DMAE crosses the blood-brain barrier and undergoes sequential methylation by phosphatidylethanolamine N-methyltransferase (PEMT), converting phosphatidylethanolamine (PE) to phosphatidylcholine (PC) in neuronal membranes. DMAE also serves as a precursor for acetylcholine (ACh) synthesis via choline kinase-mediated phosphorylation (PMID: 3305166).

Lipofuscin Clearance & Lysosomal Function

Centrophenoxine's most distinctive pharmacological property is its ability to reduce lipofuscin accumulation in neurons — the age-related "wear and tear" pigment composed of oxidized lipids, cross-linked proteins, and metals trapped in residual lysosomes. Centrophenoxine enhances lysosomal enzyme activity (acid phosphatase, cathepsin D) and autophagy flux, promoting degradation and clearance of lipofuscin granules. Animal studies demonstrate 25-40% reduction in neuronal lipofuscin content after 3-6 months of treatment, correlating with improved cognitive performance in aged subjects (PMID: 7211776).

Membrane Phospholipid Turnover

By enhancing PE-to-PC conversion via PEMT, centrophenoxine increases the PC/PE ratio in neuronal membranes, improving membrane fluidity, receptor mobility, and ion channel function. Increased phosphatidylcholine content also enhances glucose transporter (GLUT1) incorporation into neuronal membranes, improving cerebral glucose uptake and utilization. The pCPA moiety may additionally contribute to membrane effects through its lipophilic interactions with phospholipid bilayers (PMID: 6194901).

RNA Synthesis & Gene Expression

Centrophenoxine increases total RNA content in aging neurons, including mRNA, rRNA, and tRNA, by enhancing RNA polymerase II activity. This reverses the age-related decline in protein synthesis capacity, restoring production of synaptic proteins, neurotransmitter receptors, and structural cytoskeletal elements essential for neuronal maintenance (PMID: 6887836).

Reconstitution Calculator

Research

Safety Profile

Common Side Effects

• Insomnia and restlessness, particularly when taken later in the day (centrophenoxine has mild stimulant properties)
• Nausea and gastrointestinal upset
• Headache, especially during initial use or at higher doses
• Dizziness and mild agitation
• Muscle tension or jaw clenching (uncommon)
• Increased irritability or anxiety in sensitive individuals
• Body odor changes: some users report a fishy smell due to DMAE (dimethylaminoethanol) metabolite trimethylamine

Serious Adverse Effects

• Cholinergic excess symptoms at high doses: excessive salivation, lacrimation, urination, diarrhea, and gastrointestinal distress (SLUDGE syndrome)
• Seizures have been reported in animal studies at very high doses; theoretical risk in humans, especially in seizure-prone individuals
• Depression or mood disturbances with chronic high-dose use
• Hepatotoxicity has not been well-characterized in humans but cannot be excluded with prolonged high-dose use
• Rare allergic or hypersensitivity reactions

Contraindications

• Seizure disorders (epilepsy): centrophenoxine may lower seizure threshold
• Bipolar disorder or major depression: cholinergic modulation may exacerbate mood instability
• Pregnancy and breastfeeding: contraindicated due to insufficient safety data and potential developmental effects from DMAE component
• Known hypersensitivity to meclofenoxate, DMAE, or pCPA (para-chlorophenoxyacetic acid)
• Parkinson's disease patients on anticholinergic therapy: centrophenoxine's cholinergic effects may counteract treatment

Drug Interactions

• Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine): additive cholinergic effects may cause excessive acetylcholine activity
• Anticholinergic medications (atropine, benztropine, certain antihistamines): opposing mechanisms may reduce efficacy of either agent
• Racetam-class nootropics (piracetam, aniracetam): commonly combined in nootropic stacks, but the combination may amplify cholinergic side effects
• CNS stimulants (caffeine, amphetamines, modafinil): potential for additive stimulation, increasing anxiety and insomnia risk
• Lithium: theoretical interaction through cholinergic pathways; monitor closely

Special Populations

• Elderly: centrophenoxine has been studied primarily in aging populations for cognitive support; start at low doses (250 mg/day) and titrate gradually
• Children: safety not established; use is not recommended
• Hepatic or renal impairment: use with caution; reduced clearance may increase side effect risk

Pharmacokinetic Profile